Schaeybroeck et al. demonstrated that MEK inhibitors block the activity of the ERK-dependent metalloprotease ADAM17 (Van Schaeybroeck et al., 2011), which subsequently enhances c-MET-JAK1/2-STAT3 signaling that is essential for the survival of KRAS-mutated CRC but not WT KRAS (Van Schaeybroeck et al., 2014). This evidence concerns the gene KRAS and colorectal carcinoma.